Hudson Bay Capital Management
AIM

Hudson Bay Capital Management’s AIM ImmunoTech AIM Stock Holding History

Hudson Bay Capital Management’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,279
Closed -$327K – 683
2020
Q1 		$327K Buy
+1,279
New +$201K 0.01% 386
2019
Q4 		– Sell
-3,953
Closed -$301K – 572
2019
Q3 		$301K Buy
+3,953
New +$957K 0.01% 355

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SAMH
Shanda Asset Management Holdings Tortola,, British Virgin Islands $1.85B AUM 36.09% 1-Year Est. Return

Hudson Bay Capital Management's AIM Position: Q2 2020 in Review

Hudson Bay Capital Management sold out of AIM ImmunoTech (AIM) in Q2 2020, closing a stake of 1,279 shares — an estimated $327K sold.

Hudson Bay Capital Management first reported a position in AIM in Q3 2019 and held it in 2 quarters. The position peaked at $327K in Q1 2020. 22 funds tracked by Wall St. Rank hold AIM as of Q2 2020.

  • Hudson Bay Capital Management reported no remaining AIM ImmunoTech position as of Q2 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,279 AIM ImmunoTech shares in Q2 2020, an estimated $327K.
  • Hudson Bay Capital Management first reported a position in AIM ImmunoTech in Q3 2019 and held it in 2 quarters.
  • Hudson Bay Capital Management's AIM ImmunoTech position peaked at $327K in Q1 2020.
  • 22 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2020.

Based on Hudson Bay Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.